Oxford BioDynamics (OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. OBD aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare with a portfolio of clinical tests and research tools based on its proprietary EpiSwitch® technology,
uniquely capable of reproducibly translating 3D genome regulation for clinical application. The company’s flagship product, EpiSwitch CiRT (Checkpoint inhibitor Response Test), is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. The company is partnering with CLIA-certified commercial labs to deliver these important tests into the hands of physicians to meet demand and help patients as quickly as possible. OBD’s commercial team has an office in Gaithersburg, MD, USA, and the company has an ISO-certified laboratory in Penang, Malaysia. OBD has participated in 40+ partnerships with pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostics, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from 10,000+ samples in 30+ human diseases. OBD’s proprietary EpiSwitch technology maps this 3D architecture at scale, identifying abnormal configurations that can be used to diagnose patients or predict how someone may respond to a disease or treatment. For more information, please visit oxfordbiodynamics.com.
